NASDAQ:OTIC - Otonomy Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Otonomy Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.20 +0.16 (+5.26 %) (As of 02/28/2020 01:19 PM ET) Add Compare Today's Range$2.95Now: $3.20▼$3.2050-Day Range$3.04MA: $3.46▼$3.9752-Week Range$2.10Now: $3.20▼$4.18Volume4,654 shsAverage Volume209,943 shsMarket Capitalization$98.40 millionP/E RatioN/ADividend YieldN/ABeta2.75 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC Previous Symbol CUSIPN/A CIK1493566 Webhttp://www.otonomy.com/ Phone619-323-2200Debt Debt-to-Equity Ratio0.60 Current Ratio6.66 Quick Ratio6.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$750,000.00 Price / Sales131.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book1.23Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-50,370,000.00 Net Margins-6,516.78% Return on Equity-72.06% Return on Assets-45.67%Miscellaneous Employees49 Outstanding Shares30,750,000Market Cap$98.40 million Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive OTIC News and Ratings via Email Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OTIC Rates by TradingView Otonomy (NASDAQ:OTIC) Frequently Asked Questions What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." How were Otonomy's earnings last quarter? Otonomy Inc (NASDAQ:OTIC) released its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.11. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.11 million. Otonomy had a negative return on equity of 72.06% and a negative net margin of 6,516.78%. View Otonomy's Earnings History. When is Otonomy's next earnings date? Otonomy is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Otonomy. What price target have analysts set for OTIC? 4 analysts have issued twelve-month price targets for Otonomy's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate Otonomy's stock price to reach $7.00 in the next year. This suggests a possible upside of 118.8% from the stock's current price. View Analyst Price Targets for Otonomy. What is the consensus analysts' recommendation for Otonomy? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy. What are Wall Street analysts saying about Otonomy stock? Here are some recent quotes from research analysts about Otonomy stock: 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (1/7/2020) 2. HC Wainwright analysts commented, "Our $8 12-month target is based on a 60% probability of success adjusted DCF. We only include in our model—assuming 2022 launch and over $300M peak sales—and do not include any contribution from the early-stage pipeline. Our DCF reflects a 12% WACC discount rate and 1% terminal growth beyond 2028, which we think is appropriate assuming IP into the 2030s, and a likely high generic bioequivalence bar for locally acting therapy, requiring a head-to-head clinical trial." (8/29/2019) Has Otonomy been receiving favorable news coverage? Media stories about OTIC stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Otonomy earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Otonomy. Are investors shorting Otonomy? Otonomy saw a decline in short interest during the month of February. As of February 14th, there was short interest totalling 130,300 shares, a decline of 29.1% from the January 30th total of 183,800 shares. Based on an average trading volume of 193,200 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the shares of the stock are sold short. View Otonomy's Current Options Chain. Who are some of Otonomy's key competitors? Some companies that are related to Otonomy include INDIVIOR PLC/S (INVVY), DURECT (DRRX), ProQR Therapeutics (PRQR), Urovant Sciences (UROV), Xenon Pharmaceuticals (XENE), Calithera Biosciences (CALA), Lannett (LCI), Mallinckrodt (MNK), Avid Bioservices (CDMO), Rigel Pharmaceuticals (RIGL), Recro Pharma (REPH), OrganiGram (OGI), Verrica Pharmaceuticals (VRCA), CytomX Therapeutics (CTMX) and Dynavax Technologies (DVAX). What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Corbus Pharmaceuticals (CRBP), Catabasis Pharmaceuticals (CATB), Melinta Therapeutics (MLNT), Novavax (NVAX), Inovio Pharmaceuticals (INO), Intercept Pharmaceuticals (ICPT), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Coherus Biosciences (CHRS) and Opko Health (OPK). Who are Otonomy's key executives? Otonomy's management team includes the folowing people: Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)Dr. David Allen Weber, Pres, CEO & Director (Age 59)Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel Who are Otonomy's major shareholders? Otonomy's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.31%), Sofinnova Investments Inc. (4.93%), Ikarian Capital LLC (3.47%), Mercer Global Advisors Inc. ADV (0.45%), Bank of America Corp DE (0.44%) and Jacobs Levy Equity Management Inc. (0.22%). View Institutional Ownership Trends for Otonomy. Which institutional investors are selling Otonomy stock? OTIC stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for Otonomy. Which institutional investors are buying Otonomy stock? OTIC stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Renaissance Technologies LLC, Mercer Global Advisors Inc. ADV and Sofinnova Investments Inc.. View Insider Buying and Selling for Otonomy. How do I buy shares of Otonomy? Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $3.20. How big of a company is Otonomy? Otonomy has a market capitalization of $98.40 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy. What is Otonomy's official website? The official website for Otonomy is http://www.otonomy.com/. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected] MarketBeat Community Rating for Otonomy (NASDAQ OTIC)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 297 (Vote Outperform)Underperform Votes: 289 (Vote Underperform)Total Votes: 586MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: P/E Growth (PEG)
